Depression and GLP-1 Medications: What to Know (2026)

Last reviewed: June 9, 2026

Last updated: June 9, 2026

Written by: Jay Hastings, CEO of PlexusDx

Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.

Medically reviewed by: Jayden Lee, PharmD, EMBA

Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.

This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.

GLP-1 receptor agonists have transformed weight loss treatment, with semaglutide showing average weight loss of 10–15% in clinical trials. However, recent reports linking these medications to mood changes and suicidal thoughts have prompted important conversations about mental health safety. PlexusDx provides evidence-based information to help patients make informed choices about compounded GLP-1 therapy.

What Research Shows About GLP-1 and Depression Risk

Clinical trial data on GLP-1 medications and depression remains limited but growing. The Semaglutide Cardiovascular Outcomes Research in Patients with Obesity (SELECT) trial, which included over 17,500 participants, found suicidal behavior events reported in 0.51% of semaglutide users versus 0.14% of placebo recipients. While this represents a numerical increase, causality has not been definitively established, and rates remain rare overall. Ongoing pharmacovigilance through FDA monitoring continues to evaluate this potential signal.

Depression and obesity share bidirectional relationships—weight gain can worsen mood, and depression can impede weight loss efforts. Some patients report improved mental health after weight loss on GLP-1 therapy, while others experience mood changes. Individual responses vary widely based on genetics, baseline mental health status, and other medications. PlexusDx recognizes these variations and uses precision genetic testing to identify patients who may have different peptide pathway sensitivities.

How GLP-1 Medications Affect Brain Chemistry and Mood

GLP-1 receptors exist throughout the brain, including regions that regulate reward, motivation, and mood. When semaglutide or tirzepatide activate these receptors, they influence dopamine and serotonin pathways—neurotransmitters central to emotional well-being. Rapid weight loss itself can trigger metabolic shifts that affect hormone levels like leptin and cortisol, which interact with mood-regulating systems. These complex interactions explain why two patients on identical GLP-1 doses may experience different psychological effects.

The GLP-1R rs6923761 genetic variant, one of the key polymorphisms measured by PlexusDx's Precision Peptide Genetic Test, influences how efficiently your body processes GLP-1 signaling in brain tissue. Patients carrying certain variants may have heightened or reduced sensitivity to GLP-1's neurological effects, potentially affecting both efficacy and mood-related tolerability. Understanding your genetic profile allows PlexusDx providers to match therapy intensity to your unique biology.

Depression Screening and Mental Health Monitoring on GLP-1 Therapy

Patients beginning GLP-1 treatment should undergo baseline mental health assessment, including screening for depression, anxiety, and suicidal ideation using validated tools like the Patient Health Questionnaire-9 (PHQ-9). Those with a personal or family history of mood disorders, bipolar disorder, or prior suicidal attempts require closer monitoring and may benefit from combined psychiatric care. PlexusDx providers emphasize establishing a mental health baseline before starting semaglutide or tirzepatide, ensuring any mood changes can be quickly identified and addressed.

Monthly check-ins during the first three months of GLP-1 therapy should include direct questions about mood, sleep quality, energy levels, and any intrusive thoughts. Patients should report new or worsening depression, anxiety, behavioral changes, or suicidal thoughts immediately to their healthcare provider rather than stopping medication without guidance. Mental health support—whether therapy, medication adjustment, or peer support—complements GLP-1 weight loss treatment rather than replacing it. PlexusDx connects patients to mental health resources and coordinates care with prescribing providers.

Personalized GLP-1 Treatment: Genetic Testing and Risk Stratification

PlexusDx's Precision Peptide Genetic Test maps 14 peptide pathways and 49 peptides to identify how your genetics influence response to GLP-1 medications and other weight-regulating hormones. Four key variants—GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313—provide insights into your inherent sensitivity to GLP-1 signaling, appetite suppression, and metabolic efficiency. This 150+ genetic insight panel costs $99 as an add-on after your first month of treatment, allowing providers to refine your dose and compound selection.

Patients with genetic profiles indicating heightened GLP-1 sensitivity may achieve weight loss results at lower doses, potentially reducing the risk of rapid metabolic shifts that could destabilize mood. Others with lower genetic sensitivity might benefit from dual-compound therapy like GLP-Squared Injection (semaglutide plus tirzepatide starting at $249/month) to optimize results without excessive dose escalation. Unlike flat per-compound pricing models that charge more for higher doses, PlexusDx maintains flat monthly pricing—your dose may need to go up, your price won't. This transparency removes barriers to personalized care and ensures genetic insights drive clinical decisions, not cost concerns.

How Your Genetics Influence GLP-1 Response

Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.

Access Personalized GLP-1 Care Through PlexusDx

PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.

Frequently Asked Questions

Can GLP-1 medications cause depression?

Current evidence suggests GLP-1 medications do not directly cause clinical depression in most users. However, some patients report mood changes, and rare cases of suicidal ideation have been reported in post-marketing surveillance. Individual risk depends on genetics, baseline mental health, rapid weight loss speed, and concurrent medications. PlexusDx recommends baseline mental health screening and close monitoring, especially for patients with depression history.

What does clinical trial data say about GLP-1 and suicidal thoughts?

The SELECT trial found suicidal behavior events in 0.51% of semaglutide recipients versus 0.14% on placebo—a signal that warrants monitoring but remains rare overall. Causality has not been established; weight loss, metabolic changes, and unmasking of underlying mental illness may all contribute. The FDA continues pharmacovigilance, and PlexusDx providers stay current with emerging safety data to inform patient counseling.

How does PlexusDx pricing work if I need dose increases?

PlexusDx compounded semaglutide injection starts at $149 per month flat, regardless of dose level. Whether you remain on a microdose or advance to therapeutic levels, your monthly price stays the same—your dose may need to go up, your price won't. This model ensures personalized dosing is driven by clinical need, not cost barriers.

Should I stop taking GLP-1 if I develop depression?

Do not stop GLP-1 medication without consulting your prescriber. Abrupt discontinuation can cause rapid weight regain and metabolic rebound. Instead, contact your PlexusDx provider or mental health professional immediately to discuss mood changes, adjust dosing, modify the compound, or add psychiatric support. Coordinated care addresses both weight and mental health safety.

How does the Precision Peptide Genetic Test help with depression risk?

PlexusDx's $99 genetic test identifies variants like GLP1R rs6923761 that influence your brain's sensitivity to GLP-1 signaling and mood-related pathways. Results guide personalized dosing and compound selection to match your genetics, potentially reducing rapid metabolic shifts that could trigger mood instability. Testing enables precision medicine rather than one-size-fits-all dosing.

Related Reading

• Glp 1 Medications
• Do Genetic Tests Help Identify People Who Will Benefit From Glp 1 Medications
• Can A Dna Test Reveal If I Will Benefit From Glp 1 Medications
• Maximus Glp 1

Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.

Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.

Medical and Editorial Standards

Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.

Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.

Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.

Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.